MetaCap

Relmada Therapeutics (RLMD) News

NASDAQ: RLMDHealth CareBiotechnology: Pharmaceutical PreparationsUSD

2.62-0.49 (-15.76%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

RLMD news summary

We found 5 recent headlines mentioning Relmada Therapeutics (RLMD): 2 in the past week and 5 in the past 30 days, most often from GlobeNewswire, Nasdaq. RLMD is making an outsized move today, down 15.76% at $2.62, which often coincides with company-specific news. Check the latest headlines below for the likely catalyst. The most recent story, "Relmada Therapeutics, Inc. Appoints Jørn Skibsted Jakobsen, MD, PhD, as Chief Development Officer", was published by Nasdaq on Nov 16, 2026.

Headlines link to the original publishers. MetaCap does not republish third-party articles.

Summary generated from market data by MetaCap's automated system. Methodology

Latest Relmada Therapeutics headlines

Compare RLMD